ACHV - Achieve Life Sciences, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Vancouver,
Canada
Type: Equity
ACHV price evolution
ACHV
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $14.76 | $66.4 | $15.55 | |
| Short term investments | $46.56 | |||
| Net receivables | $0.11 | |||
| Inventory | ||||
| Total current assets | $45.53 | $62.52 | $67.71 | $16.98 |
| Long term investments | $0.09 | |||
| Property, plant & equipment | $0.02 | $0.04 | $0.05 | $0.07 |
| Goodwill & intangible assets | $2.12 | $2.17 | $2.23 | |
| Total noncurrent assets | $2.27 | $2.32 | $2.39 | |
| Total investments | $46.56 | $0.09 | ||
| Total assets | $47.92 | $64.79 | $70.03 | $19.37 |
| Current liabilities | ||||
| Accounts payable | $1.01 | $0.55 | $0.37 | $0.62 |
| Deferred revenue | ||||
| Short long term debt | $8.84 | $17.19 | $16.73 | |
| Total current liabilities | $6.72 | $13.7 | $20.57 | $20.81 |
| Long term debt | $9.82 | $8.8 | $0.01 | |
| Total noncurrent liabilities | $8.8 | $0.01 | ||
| Total debt | $17.64 | $17.19 | $16.73 | |
| Total liabilities | $16.54 | $22.51 | $20.57 | $20.82 |
| Shareholders' equity | ||||
| Retained earnings | -$193.22 | -$180.71 | -$172.25 | -$165.75 |
| Other shareholder equity | $0.07 | -$0.01 | $0 | $0 |
| Total shareholder equity | $42.28 | $49.46 | -$1.45 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $15.55 | $24.77 | $43.02 | $35.9 |
| Short term investments | ||||
| Net receivables | $0.11 | $0.1 | $0.15 | |
| Inventory | ||||
| Total current assets | $16.98 | $27.33 | $44.59 | $36.98 |
| Long term investments | $0.09 | $0.07 | ||
| Property, plant & equipment | $0.07 | $0.13 | $0.06 | $0.19 |
| Goodwill & intangible assets | $2.23 | $2.45 | $2.67 | $2.9 |
| Total noncurrent assets | $2.39 | $2.64 | $2.92 | $3.32 |
| Total investments | $0.09 | $0.07 | ||
| Total assets | $19.37 | $29.97 | $47.52 | $40.3 |
| Current liabilities | ||||
| Accounts payable | $0.62 | $1.66 | $0.84 | $0.33 |
| Deferred revenue | ||||
| Short long term debt | $16.73 | $16.13 | $0.07 | $0.09 |
| Total current liabilities | $20.81 | $21.6 | $4.55 | $2.94 |
| Long term debt | $0.01 | $0.07 | $14.92 | $0.08 |
| Total noncurrent liabilities | $0.01 | $0.07 | $14.92 | $0.08 |
| Total debt | $16.73 | $16.2 | $14.99 | $0.17 |
| Total liabilities | $20.82 | $21.67 | $19.47 | $3.01 |
| Shareholders' equity | ||||
| Retained earnings | -$165.75 | -$135.94 | -$93.59 | -$60.43 |
| Other shareholder equity | $0 | $0 | $0 | $0 |
| Total shareholder equity | -$1.45 | $8.3 | $28.04 | $37.29 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $5.11 | $2.8 | $2.11 | |
| Selling, general & administrative | $3.32 | $3.18 | $2.27 | |
| Total operating expenses | $8.43 | $5.98 | $4.39 | |
| Operating income | -$8.43 | -$5.98 | -$4.39 | |
| Income from continuing operations | ||||
| EBIT | -$7.66 | -$5.68 | -$4.69 | |
| Income tax expense | ||||
| Interest expense | $0.8 | $0.81 | $0.79 | |
| Net income | ||||
| Net income | -$8.46 | -$6.49 | -$5.48 | |
| Income (for common shares) | -$8.46 | -$6.49 | -$5.48 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $15.81 | $30.08 | $23.97 | $6.88 |
| Selling, general & administrative | $11.44 | $10.72 | $9.13 | $7.87 |
| Total operating expenses | $27.25 | $40.8 | $33.09 | $14.75 |
| Operating income | -$27.25 | -$40.8 | -$33.09 | -$14.75 |
| Income from continuing operations | ||||
| EBIT | -$26.96 | -$40.56 | -$33.15 | -$14.73 |
| Income tax expense | ||||
| Interest expense | $2.85 | $1.79 | ||
| Net income | ||||
| Net income | -$29.82 | -$42.35 | -$33.15 | -$14.73 |
| Income (for common shares) | -$29.82 | -$42.35 | -$33.15 | -$14.73 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$8.46 | -$6.49 | -$5.48 | |
| Operating activities | ||||
| Depreciation | $0.06 | $0.06 | $0.06 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $1.45 | $1.29 | -$0.01 | |
| Total cash flows from operations | -$4.92 | -$5.29 | -$4.36 | |
| Investing activities | ||||
| Capital expenditures | -$0.01 | |||
| Investments | ||||
| Total cash flows from investing | -$33.3 | -$0.01 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$0.04 | $56.11 | ||
| Net borrowings | ||||
| Total cash flows from financing | $47.84 | -$0.15 | $56.11 | |
| Effect of exchange rate | $0 | -$0 | ||
| Change in cash and equivalents | -$6.03 | -$51.64 | $50.82 | -$4.37 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$29.82 | -$42.35 | -$33.15 | -$14.73 |
| Operating activities | ||||
| Depreciation | $0.23 | $0.24 | $0.25 | $0.26 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $3.44 | $3.27 | $2.19 | $1.29 |
| Total cash flows from operations | -$24.48 | -$37.55 | -$29.44 | -$13.47 |
| Investing activities | ||||
| Capital expenditures | -$0.02 | -$0.02 | ||
| Investments | ||||
| Total cash flows from investing | -$0.02 | -$0.02 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $15.5 | $19.36 | $21.68 | $32.73 |
| Net borrowings | -$0.02 | $14.93 | ||
| Total cash flows from financing | $15.28 | $19.3 | $36.61 | $32.68 |
| Effect of exchange rate | -$0 | $0 | -$0 | |
| Change in cash and equivalents | -$9.22 | -$18.25 | $7.17 | $19.19 |
News
Fundamentals
| Market cap | $116.24M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 34.39M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | -14.38 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 6.78 |
| Quick ratio | N/A |